Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
Chemmedchem|December 22, 2017
Structure-Based Design of Selective Noncovalent CDK12 InhibitorsJeffrey W Johannes, Christopher R Denz, Nancy Su, et al.Proceedings of the National Academy of Sciences of the United States of America|October 29, 2015
HER2 missense mutations have distinct effects on oncogenic signaling and migrationDaniel J Zabransky, Christopher L Yankaskas, Rory L Cochran, et al.Oncotarget|January 30, 2016
Ki-67 is required for maintenance of cancer stem cells but not cell proliferationJustin Cidado, Hong Yuen Wong, D Marc Rosen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 8, 2014
Detection of cancer DNA in plasma of patients with early-stage breast cancerJulia A Beaver, Danijela Jelovac, Sasidharan Balukrishna, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2015
ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer PatientsDavid Chu, Costanza Paoletti, Christina Gersch, et al.Communications Biology|January 26, 2021
Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapyClaire M Patterson, Srividya B Balachander, Iain Grant, et al.Proceedings of the National Academy of Sciences of the United States of America|October 12, 2011
Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cellsHiroyuki Konishi, Morassa Mohseni, Akina Tamaki, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2020
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting ThrombocytopeniaSrividya B Balachander, Steven W Criscione, Kate F Byth, et al.Journal of Medicinal Chemistry|December 11, 2020
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological MalignanciesBernard Barlaam, Robert Casella, Justin Cidado, et al.Nature Communications|December 19, 2018
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemiaAdriana E Tron, Matthew A Belmonte, Ammar Adam, et al.Pageof 4